PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Colistin→

Colistin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1264-72-8
Molecular formula
C52H98N16O13
Molecular weight
1155.4 g/mol
Drug class
Polymyxin E cyclic lipopeptide antibacterialouter-membrane disruptor
Mechanism of action
Binds lipopolysaccharide and phospholipids in the outer membrane of Gram-negative bacteria, displacing stabilising divalent cations and disrupting membrane integrity, causing leakage of intracellular contents and bacterial death.
Indications / reported uses
  • Treatment of serious infections caused by susceptible multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii and selected Enterobacterales, using systemic formulations under specialist supervision
  • Topical or otic formulations have separate route-specific indications; systemic use is limited by nephrotoxicity and neurotoxicity

Sources: US DailyMed — Colistimethate sodium/colistin products · NLM MeSH — Colistin · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Colistin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Colistin Permitted Daily Exposure (PDE) report (the Colistin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Colistin Occupational Exposure Limit (OEL) report (the Colistin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.